
|Videos|April 8, 2022
Residual Cardiovascular Risk
Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
Value-Based Care Offers Solutions to Patient Access Challenges: Brian Mulherin, MD
3
New WHO Reports Sounds Alarm on Antimicrobial Resistance
4
Why Education and Collaboration Are Key to Bispecific Therapy Administration: Amir Fathi, MD
5